|
| Press Releases |
|
 |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
| Wednesday, December 18, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which marks the official beginning of this new therapy benefiting patients in mainland China. more info >> |
|
| Tuesday, December 17, 2024 |
|
|
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Administration (NMPA) of China has officially accepted the New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). VELSIPITY is an effective and convenient, once-daily, oral treatment for patients with moderately to severely active UC. more info >> |
|
| Thursday, December 12, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY(R) (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau. more info >> |
|
| Wednesday, December 11, 2024 |
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership |
| As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise. more info >> |
|
| Wednesday, December 4, 2024 |
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy |
| Everest Medicines (HKEX 1952.HK,"Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. more info >> |
|
| Monday, December 2, 2024 |
|
|
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong |
| Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everests New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. more info >> |
|
| Friday, November 29, 2024 |
|
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL) |
| On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the 'National Reimbursement Drug List (2024)' (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL. more info >> |
|
| Tuesday, November 19, 2024 |
|
|
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea |
| Today, Everest Medicines announced that NEFECON(R) has received full approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion =1.0 g/day (or urine protein-to-creatinine ratio =0.8 g/g). This approval further expands NEFECON(R)'s footprint in Asia and provides Asian patients with a groundbreaking etiological treatment option for IgAN. more info >> |
|
| Friday, October 25, 2024 |
|
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
'Behind the Canvas Series 1: Jean-Michel Basquiat' Makes Its Global Debut in Singapore
Jan 8, 2025 22:44 HKT/SGT
|
|
|
Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
Jan 8, 2025 22:30 HKT/SGT
|
|
|
Sparkline Hosts Exclusive Webinar on Leveraging Google Analytics 4 for E-Commerce Success 
Jan 8, 2025 18:00 HKT/SGT
|
|
|
Honda Presents World Premiere of Honda 0 Saloon and Honda 0 SUV Prototypes at CES 2025
Jan 8, 2025 17:32 JST
|
|
|
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
Jan 8, 2025 12:30 JST
|
|
|
The Quantum Revolution. How Quantum Computing Will Transform the Global Economy in the Next Decade
Jan 8, 2025 08:30 HKT/SGT
|
|
|
Graid Technology Unveils SupremeRAID(TM) AE: The AI Edition Designed for GPU-Driven AI Workloads
Jan 7, 2025 22:00 HKT/SGT
|
|
|
Asian Financial Forum held next week as the region's first major international financial assembly of 2025
Jan 7, 2025 18:56 HKT/SGT
|
|
|
Mitsubishi Motors to Display Custom Versions of the Triton at Tokyo Auto Salon 2025
Jan 7, 2025 15:41 JST
|
|
|
CleverTap Predicts Key Trends for Customer Engagement in 2025
Jan 7, 2025 14:30 HKT/SGT
|
|
|
'Toyota Woven City,' a Test Course for Mobility, Completes Phase 1 Construction and Prepares for Launch
Jan 7, 2025 15:25 JST
|
|
|
$INDX Token Pre-Sale Kicks Off as CryptoIndex.com Paves the Way for Decentralized Indexing
Jan 7, 2025 12:00 HKT/SGT
|
|
|
Stableton Partners with Alta to Expand Access to Global High-Growth Pre-IPO Investments
Jan 7, 2025 11:02 HKT/SGT
|
|
|
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Jan 7, 2025 9:14 JST
|
|
|
Spectral Achieves Major Patent Milestone Related to Quantum Computing
Jan 6, 2025 22:37 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
